uk 68798 has been researched along with vernakalant in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saklani, P; Skanes, A | 1 |
| Beekman, JD; Tieland, RG; van der Heyden, MA; Varkevisser, R; Vos, MA | 1 |
1 review(s) available for uk 68798 and vernakalant
| Article | Year |
|---|---|
Novel anti-arrhythmic medications in the treatment of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Digoxin; Dronedarone; Forecasting; Heart Failure; Humans; Phenethylamines; Piperazines; Pyrrolidines; Ranolazine; Sulfonamides; Technology, Pharmaceutical; Ventricular Dysfunction, Left | 2012 |
1 other study(ies) available for uk 68798 and vernakalant
| Article | Year |
|---|---|
Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model.
Topics: Animals; Anisoles; Anti-Arrhythmia Agents; Atrioventricular Block; Disease Models, Animal; Dogs; Female; Male; Phenethylamines; Pyrrolidines; Sulfonamides; Torsades de Pointes | 2013 |